Compare CCI & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCI | NTRA |
|---|---|---|
| Founded | 1994 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.6B | 32.9B |
| IPO Year | 1998 | 2015 |
| Metric | CCI | NTRA |
|---|---|---|
| Price | $86.39 | $206.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 14 |
| Target Price | $110.47 | ★ $253.79 |
| AVG Volume (30 Days) | ★ 3.0M | 1.1M |
| Earning Date | 02-04-2026 | 02-26-2026 |
| Dividend Yield | ★ 4.94% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.01 | N/A |
| Revenue | ★ $4,264,000,000.00 | $2,116,676,000.00 |
| Revenue This Year | N/A | $33.95 |
| Revenue Next Year | N/A | $16.72 |
| P/E Ratio | $85.09 | ★ N/A |
| Revenue Growth | N/A | ★ 38.17 |
| 52 Week Low | $83.21 | $125.38 |
| 52 Week High | $115.76 | $256.36 |
| Indicator | CCI | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 47.44 | 26.35 |
| Support Level | $83.91 | $229.14 |
| Resistance Level | $87.04 | $236.58 |
| Average True Range (ATR) | 2.07 | 9.02 |
| MACD | -0.08 | -3.25 |
| Stochastic Oscillator | 31.63 | 1.51 |
Crown Castle owns or manages roughly 40,000 wireless towers in the United States. It leases space on its towers to wireless service providers, which install equipment to support their wireless networks. The company has a very concentrated customer base, with about 75% of its revenue from the Big Three US mobile carriers: Verizon, T-Mobile, and AT&T. Crown has plans to divest its fiber business, which is expected to be finalized in 2026. After that, it will be a stand-alone tower operator. Crown Castle operates as a real estate investment trust.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.